IRIS
FABBIANI, MASSIMILIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.953
NA - Nord America 3.972
AS - Asia 856
SA - Sud America 173
AF - Africa 55
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 5
Totale 10.022
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.928
IT - Italia 1.562
IE - Irlanda 782
GB - Regno Unito 777
SG - Singapore 370
RU - Federazione Russa 353
DE - Germania 322
SE - Svezia 280
CN - Cina 269
FR - Francia 220
UA - Ucraina 196
FI - Finlandia 191
BR - Brasile 147
NL - Olanda 77
CI - Costa d'Avorio 42
VN - Vietnam 42
ES - Italia 39
IN - India 31
AT - Austria 25
CZ - Repubblica Ceca 24
CA - Canada 23
BE - Belgio 22
HK - Hong Kong 19
IR - Iran 18
PL - Polonia 15
MX - Messico 12
TR - Turchia 12
AE - Emirati Arabi Uniti 9
BG - Bulgaria 9
AR - Argentina 8
EU - Europa 7
LT - Lituania 7
PT - Portogallo 7
AZ - Azerbaigian 6
CH - Svizzera 6
DK - Danimarca 6
EC - Ecuador 6
IL - Israele 6
LV - Lettonia 6
PH - Filippine 6
TW - Taiwan 6
AU - Australia 5
IQ - Iraq 5
SA - Arabia Saudita 5
UZ - Uzbekistan 5
AL - Albania 4
CY - Cipro 4
MA - Marocco 4
MK - Macedonia 4
RO - Romania 4
TH - Thailandia 4
AM - Armenia 3
CL - Cile 3
CO - Colombia 3
EE - Estonia 3
HR - Croazia 3
JP - Giappone 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
MY - Malesia 3
NG - Nigeria 3
BD - Bangladesh 2
BH - Bahrain 2
BY - Bielorussia 2
EG - Egitto 2
GR - Grecia 2
JM - Giamaica 2
KH - Cambogia 2
KR - Corea 2
LU - Lussemburgo 2
MD - Moldavia 2
NP - Nepal 2
PE - Perù 2
PK - Pakistan 2
QA - Qatar 2
SV - El Salvador 2
ZA - Sudafrica 2
A1 - Anonimo 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
GE - Georgia 1
ID - Indonesia 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PY - Paraguay 1
SN - Senegal 1
UY - Uruguay 1
VE - Venezuela 1
Totale 10.022
Salva come PNG Salva come JPEG
Città #
Dublin 768
Southend 686
Santa Clara 452
Fairfield 426
Chandler 389
Ashburn 316
Milan 299
Siena 292
Woodbridge 236
Houston 190
Seattle 177
Wilmington 167
Helsinki 159
Jacksonville 158
Cambridge 152
Singapore 148
Munich 139
Ann Arbor 128
Florence 117
Princeton 109
Rome 84
New York 76
Nuremberg 48
Nanjing 47
Abidjan 42
Brescia 42
Los Angeles 40
Dong Ket 39
Menlo Park 39
Boardman 34
San Diego 32
Shanghai 32
Lauterbourg 31
Málaga 31
Beijing 29
Brussels 22
Moscow 20
Portsmouth 20
Fremont 19
London 19
Nanchang 19
Shenyang 19
Hong Kong 17
Washington 17
San Mateo 16
Brno 15
Naples 15
Chicago 14
Düsseldorf 14
Toronto 14
Bologna 13
Vienna 12
Aachen 11
Frankfurt am Main 11
Comun Nuovo 10
Hebei 10
Jinan 10
Paris 10
Piscataway 10
Ufa 10
Hyderabad 9
Livorno 9
Newark 9
Padova 9
Poggibonsi 9
Sofia 9
Tianjin 9
Agliana 8
Carrara 8
Monteriggioni 8
Council Bluffs 7
Dallas 7
Figline Valdarno 7
Gdynia 7
Amsterdam 6
Anagni 6
Baku 6
Changsha 6
Espoo 6
Falls Church 6
Guangzhou 6
Jiaxing 6
Kunming 6
Pisa 6
Redwood City 6
Ribeirão Preto 6
Riga 6
Salerno 6
Stockholm 6
São Paulo 6
Taipei 6
Verona 6
Bacoli 5
Catania 5
Catanzaro 5
Columbus 5
Grosseto 5
Indore 5
Izmir 5
Lanciano 5
Totale 6.784
Salva come PNG Salva come JPEG
Nome #
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 313
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 236
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 230
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 222
Genetic mechanisms of critical illness in COVID-19 221
Peripheral biomarkers' panel for severe COVID-19 patients 207
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 206
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 189
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 185
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 176
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 170
Pathogen-sugar interactions revealed by universal saturation transfer analysis 169
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 168
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 157
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 152
Mapping the human genetic architecture of COVID-19 152
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 143
A first update on mapping the human genetic architecture of COVID-19 142
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 137
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 136
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 135
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 134
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 134
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 134
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 133
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 132
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 132
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study 131
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 128
Epidemiological and clinical study of viral respiratory tract infections in children from Italy 125
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 125
An explainable model of host genetic interactions linked to COVID-19 severity 116
Staphylococcus aureus: studio clinico e microbiologico 116
null 114
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 113
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-Infected Adults 111
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in virological outcomes over time 110
WES profiling of COVID-19 110
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 109
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 109
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 108
Retrospective study of tuberculosis in the Province of Siena [Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena] 106
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 105
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 103
Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing 102
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 101
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 101
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 101
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 99
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 97
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 94
Clinical and molecular characterization of COVID-19 hospitalized patients 94
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 93
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 90
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. 89
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 85
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 84
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 83
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 82
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 79
Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort 79
THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY 75
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 74
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 73
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 73
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 72
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 70
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 68
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 67
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 64
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants 63
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 62
Nucleoside Reverse-Transcriptase Inhibitor Resistance Mutations Predict Virological Failure in Human Immunodeficiency Virus-Positive Patients during Lamivudine plus Dolutegravir Maintenance Therapy in Clinical Practice 61
Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients 60
Whole-genome sequencing reveals host factors underlying critical COVID-19 57
Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patient 57
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 55
The Model for Early COvid-19 Recognition (MECOR) score: a simple, low cost, and accurate tool to discriminate between COVID-19 and community-acquired pneumonia 53
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 47
Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features 45
Colonizzazione da batteri multiresistenti nel trapianto di polmone ed eventi infettivi: studio pilota osservazionale-retrospettivo 44
Persistence of spike-specific memory B cells and antibodies nine months after two doses of BNT162b2 mRNA vaccine. 43
Third Sars-CoV-2 vaccine dose: B cell and antibody responses following heterologous and homologous vaccination strategies. 42
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability 39
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. 38
Successivi booster vaccinali contro SARS-CoV-2: risposta umorale in pazienti sottoposti a trapianto di cuore o di polmone 34
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 31
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 30
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 28
Fosfomycin as partner drug for systemic infection management. a systematic review of its synergistic properties from in vitro and in vivo studies 28
Trattamento efficace di osteomielite sternale con raccolta purulenta da Klebsiella pneumoniae multiresistente in recente trapianto di polmone 28
Programma di vaccinazione antiMpox e screening infettivologico: opportunità di prevenzione in differenti categorie a rischio 27
Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV 27
Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study 27
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 26
Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination? 25
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 25
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis 24
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 22
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 22
Totale 9.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020236 0 0 0 0 0 0 0 0 87 69 27 53
2020/2021961 22 88 53 96 73 84 36 114 94 88 101 112
2021/20221.111 105 100 43 59 67 53 56 59 87 84 150 248
2022/20231.657 100 153 172 198 134 304 115 158 142 59 73 49
2023/20241.498 71 45 167 93 72 343 435 65 15 44 56 92
2024/20253.627 170 175 388 237 927 371 564 363 432 0 0 0
Totale 10.798